Literature DB >> 16643432

Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) in Waldenström macroglobulinaemia.

Evangelos Terpos1, Athanasios Anagnostopoulos, Efstathios Kastritis, Aristotelis Bamias, Konstantinos Tsionos, Meletios-Athanassios Dimopoulos.   

Abstract

Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) and bone remodelling markers were evaluated in 38 patients with Waldenström macroglobulinaemia (WM) and correlated with clinical and laboratory variables. MIP-1alpha was elevated in WM; untreated patients had higher MIP-1alpha levels than patients in remission or with active disease after treatment. MIP-1alpha correlated with increased bone resorption, beta2-microglobulin and splenomegaly. Receptor activator of nuclear factor-kappaB ligand serum levels were elevated in WM patients; the subsequent increased bone resorption was balanced by a comparable elevation of osteoprotegerin production and bone formation. These findings may explain the absence of lytic lesions in WM patients and suggest a potential role of MIP-1alpha in WM.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16643432     DOI: 10.1111/j.1365-2141.2006.06017.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

Review 1.  Current developments in salivary diagnostics.

Authors:  Craig S Miller; Joseph D Foley; Alison L Bailey; Charles L Campell; Roger L Humphries; Nicolaos Christodoulides; Pierre N Floriano; Glennon Simmons; Bryon Bhagwandin; James W Jacobson; Spencer W Redding; Jeffrey L Ebersole; John T McDevitt
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

2.  Osteolytic bone resorption in adult T-cell leukemia/lymphoma.

Authors:  Sherry T Shu; Chelsea K Martin; Nanda K Thudi; Wessel P Dirksen; Thomas J Rosol
Journal:  Leuk Lymphoma       Date:  2010-04

3.  Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity.

Authors:  Sherine F Elsawa; Anne J Novak; Steven C Ziesmer; Luciana L Almada; Lucy S Hodge; Deanna M Grote; Thomas E Witzig; Martin E Fernandez-Zapico; Stephen M Ansell
Journal:  Blood       Date:  2011-09-14       Impact factor: 22.113

4.  Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors.

Authors:  Maurizio Zangari; Tamara Berno; Ye Yang; Ming Zeng; Hongwei Xu; Lisa Pappas; Guido Tricot; Archana Kamalakar; Donghoon Yoon; Larry J Suva
Journal:  Bone       Date:  2013-12-31       Impact factor: 4.398

5.  Increased angiogenesis and enhanced bone formation in patients with IgM monoclonal gammopathy and urticarial skin rash: new insight into the biology of Schnitzler syndrome.

Authors:  Evangelos Terpos; Bouchra Asli; Dimitrios Christoulas; Jean-Claude Brouet; Efstathios Kastritis; Michel Rybojad; Djaouida Bengoufa; Meletios A Dimopoulos; Jean Paul Fermand
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

Review 6.  The bone marrow microenvironment in Waldenström macroglobulinemia.

Authors:  Amit Agarwal; Irene M Ghobrial
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-03-13

Review 7.  Cytokines in the microenvironment of Waldenström's macroglobulinemia.

Authors:  Sherine F Elsawa; Stephen M Ansell
Journal:  Clin Lymphoma Myeloma       Date:  2009-03

8.  Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia.

Authors:  Shahrzad Jalali; Tammy Price-Troska; Jonas Paludo; Jose Villasboas; Hyo-Jin Kim; Zhi-Zhang Yang; Anne J Novak; Stephen M Ansell
Journal:  Blood Adv       Date:  2018-08-14

Review 9.  Schnitzler's syndrome: lessons from 281 cases.

Authors:  Heleen D de Koning
Journal:  Clin Transl Allergy       Date:  2014-12-05       Impact factor: 5.871

10.  Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging.

Authors:  E Kastritis; M Gavriatopoulou; M A Dimopoulos; E Eleutherakis-Papaiakovou; N Kanellias; M Roussou; C Pamboucas; S T Toumanidis; E Terpos
Journal:  Blood Cancer J       Date:  2015-06-05       Impact factor: 11.037

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.